Related by context. All words. (Click for frequent words.) 74 chlorambucil 74 Doxil ® 73 pegylated liposomal doxorubicin 73 partial remissions 72 gemcitabine carboplatin 72 gemcitabine Gemzar 72 Fludara 72 low dose cytarabine 72 Flu Cy 71 estramustine 71 daunorubicin 71 FOLFOX4 71 gemcitabine cisplatin 71 mRCC 71 Platinol 71 Camptosar ® 70 Pemetrexed 70 melphalan prednisone 70 complete cytogenetic response 70 relapsed MM 70 standard chemotherapy regimen 70 carboplatin paclitaxel 70 plus dexamethasone 70 CIMZIA ™ 70 achieved CCyR 70 hA# 70 azacytidine 70 sorafenib Nexavar 70 galiximab 70 adriamycin 70 comparator arm 70 sunitinib malate 69 azacitidine 69 FOLFIRI 69 docetaxel chemotherapy 69 CR nPR 69 idarubicin 69 Fludarabine 69 dacarbazine DTIC 69 etoposide 69 CHOP chemotherapy 69 plus prednisone 69 Irinotecan 69 clodronate 69 Elitek 69 Folfox 69 5FU 69 decitabine 69 FluCAM 69 ribavirin RBV 69 liposomal formulation 69 dacarbazine 69 pegylated interferon alpha 69 imatinib Gleevec 68 Vidaza ® 68 docetaxel prednisone 68 ritonavir boosted 68 XELOX 68 flutamide 68 IFN α 68 DOXIL 68 mapatumumab 68 CANCIDAS 68 paclitaxel Taxol 68 TMC# r 68 liposomal doxorubicin 68 Cloretazine 68 oral allopurinol 68 achieved ACR# 68 KRAS mutations occur 68 topotecan 68 Taxotere ® 68 alkylating agent 68 gefitinib Iressa 68 erlotinib Tarceva ® 68 cyclophosphamide methotrexate 68 5 Fluorouracil 68 paclitaxel carboplatin 68 oral Hycamtin 68 relapsed ovarian cancer 68 Alocrest 68 cisplatin gemcitabine 68 cetuximab Erbitux ® 68 interferon ribavirin 68 oral clodronate 68 debulking surgery 68 metastatic CRC 68 concurrent chemoradiation 68 CIMZIA TM 68 dasatinib Sprycel 68 docetaxel Taxotere 68 Trastuzumab 68 Paraplatin ® 68 FOLFOX 68 sorafenib Nexavar ® 68 mitoxantrone plus 68 pamidronate 68 goserelin 68 5-FU/LV 67 Tarceva TM 67 bevacizumab Avastin R 67 Gleevec resistant 67 fluoropyrimidine 67 bendamustine 67 refractory AML 67 cisplatin vinorelbine 67 pertuzumab 67 4mg/kg 67 Erlotinib 67 vinorelbine 67 thalidomide Thalomid 67 paclitaxel Taxol ® 67 trastuzumab Herceptin R 67 cabazitaxel 67 biochemical relapse 67 bortezomib Velcade 67 K ras mutations 67 heavily pretreated patients 67 doxorubicin cyclophosphamide 67 5 FU leucovorin 67 pCR 67 metastatic malignant 67 Hycamtin ® 67 ZOLINZA 67 gemcitabine Gemzar ® 67 receptor blocker 67 demonstrated antitumor activity 67 HBeAg positive patients 67 HBeAg 67 pegylated interferon alfa 67 CLL SLL 67 micafungin 67 Aptivus ® 67 castrate resistant 67 Paraplatin ® carboplatin 67 platinum refractory 67 lapatinib Tykerb 67 antithymocyte globulin 67 tipranavir r 67 Platinol ® cisplatin 67 Pertuzumab 67 IMC A# 67 NMIBC 67 FOLPI 67 Peg IFN 67 Nilotinib 67 TPV r 67 bleomycin 67 interferon alfa 67 vorinostat 67 CRp 67 placebo dexamethasone 66 ara C 66 tenecteplase 66 HER2 positive metastatic breast 66 systemic ALCL 66 INCB# [001] 66 capecitabine Xeloda 66 relapsed refractory multiple myeloma 66 nicardipine 66 baseline LDH 66 VNP#M 66 lymphoid malignancies 66 PEG IFN 66 bevacizumab Avastin ® 66 tipranavir 66 MabCampath 66 refractory chronic lymphocytic 66 dasatinib Sprycel ® 66 cyclophosphamide doxorubicin vincristine 66 Pegylated Interferon 66 Platinol ® 66 immunoconjugate 66 metastatic hormone refractory 66 Myelodysplastic Syndrome MDS 66 cediranib 66 docetaxel Taxotere ® 66 Halaven 66 fludarabine 66 adjuvant cisplatin 66 mg/m2 dose 66 alfa 2a 66 dose cytarabine 66 elacytarabine 66 taxane chemotherapy 66 Panzem R NCD 66 adjuvant tamoxifen 66 iniparib 66 carboplatin chemotherapy 66 leukemia AML 66 Taxotere chemotherapy 66 CCyR 66 metastatic renal cell carcinoma 66 bortezomib Velcade R 66 Copegus ribavirin 66 PegIFN RBV 66 lenalidomide dexamethasone 66 vinca alkaloid 66 pomalidomide 66 fluorouracil 66 biliary tract cancer 66 HBeAg negative patients 66 piperacillin tazobactam 66 seliciclib 66 Alkeran 66 Fulvestrant 66 caspofungin 66 mycophenolate mofetil 66 5-fluorouracil/leucovorin 66 erlotinib Tarceva 66 sargramostim 66 receptor tyrosine kinase inhibitor 66 temsirolimus 66 FUSILEV enhances 66 Velcade bortezomib 66 Dasatinib 66 bortezomib 66 leukemia CLL 66 fulvestrant 66 PEGPH# 66 nab paclitaxel 66 stage IIIb IV 66 ixabepilone 66 Gemzar ® 66 neoadjuvant 66 certolizumab 65 unfractionated heparin UFH 65 Combination therapy 65 LEXIVA r 65 boosted protease inhibitor 65 TAXOTERE R 65 cinacalcet 65 pediatric acute lymphoblastic 65 refractory CLL 65 saline placebo 65 Peginterferon 65 cytoreduction 65 Amrubicin 65 mitomycin 65 ErbB2 positive 65 adalimumab Humira 65 evaluating tivozanib 65 elotuzumab 65 APTIVUS r 65 nilotinib 65 plus gemcitabine 65 SUTENT 65 mutated KRAS 65 Vidaza azacitidine 65 ELACYT 65 recurrent glioblastoma multiforme 65 Capecitabine 65 Lenalidomide 65 lopinavir r 65 temozolomide TMZ 65 TheraGuide 65 chemoradiation therapy 65 zoledronate 65 irbesartan 65 alpha 2a 65 teriflunomide 65 intravenous cyclophosphamide 65 orally administered inhibitor 65 anthracycline taxane 65 dasatinib 65 Xanafide 65 Hormone Refractory Prostate Cancer 65 Bevacizumab 65 Pharmacokinetics PK 65 imatinib Gleevec ® 65 iodixanol 65 progression TTP 65 cytarabine daunorubicin 65 metastatic castration resistant 65 PSMA ADC 65 APTIVUS R 65 rituximab Rituxan ® 65 Panzem NCD 65 complete cytogenetic 65 FOLFOX regimen 65 Jevtana 65 heavily pretreated 65 Degarelix 65 efaproxiral 65 synthase TS 65 cytogenetic responses 65 Telintra 65 cetuximab Erbitux R 65 Taxol paclitaxel 65 trastuzumab Herceptin ® 65 splenectomized patients 65 amoxicillin clavulanate 65 receiving highly emetogenic 65 locoregional recurrence 65 5 fluorouracil leucovorin 65 irinotecan doxorubicin oxaliplatin paclitaxel 65 cyclophosphamide chemotherapy 65 Median PFS 65 lispro 65 SPRYCEL ® 65 VELCADE melphalan 65 FOLFOX6 65 nadolol 65 anti angiogenic agents 65 posaconazole 65 patients evaluable 65 HGS ETR2 65 Gemcitabine 65 dalteparin 65 EGFR tyrosine kinase inhibitor 65 cisplatin chemotherapy 65 lumiliximab 65 gemcitabine chemotherapy 65 rituximab Rituxan 65 TACE 65 AZT zidovudine Retrovir 65 Elotuzumab 65 neurologic progression 65 ZACTIMA 65 8mg/kg 65 epoetin alpha 65 Navelbine ® 65 DAPT 65 metastatic GIST 65 mCRC patients 65 Xelox 65 oxaliplatin Eloxatin 65 fludarabine cyclophosphamide 65 cancer mCRC 65 unresectable stage 65 relapsed SCLC 65 Temsirolimus 65 recurrent GBM 64 taxane therapy 64 fibrinolytic 64 dose dexamethasone 64 prostate cancer CRPC 64 Navelbine 64 paricalcitol 64 EGFR TKI 64 PegIFN 64 comparator PI r 64 hormone refractory metastatic prostate 64 postoperative chemotherapy 64 Cloretazine ® 64 imatinib 64 MGd 64 MAGE A3 ASCI 64 palifermin 64 Free Survival PFS 64 pancreatic adenocarcinoma 64 IRX 2 64 everolimus eluting stents 64 ABVD 64 Proxinium TM 64 prospectively defined 64 folinic acid 64 Bezielle 64 mg TID 64 paclitaxel cisplatin 64 EOquin TM 64 Campath alemtuzumab 64 antiandrogen 64 tumor necrosis 64 relapsed multiple myeloma 64 Doxil 64 steroid dexamethasone 64 Azacitidine 64 evaluable subjects 64 Gliadel Wafer 64 Etoposide 64 CR CRu 64 Pegasys ® 64 fluorouracil leucovorin 64 bicalutamide 64 mg kg dose 64 relapsed CLL 64 oral rivaroxaban 64 anti leukemic 64 metastatic RCC 64 axitinib 64 FOLFIRINOX 64 pegfilgrastim 64 Interferon alpha 64 ARB telmisartan 64 anthracyclines taxanes 64 Taxol ® 64 alkylating 64 antimetabolite 64 assessing T DM1 64 paclitaxel Taxol R 64 highly emetogenic 64 MCyR 64 NATRECOR R 64 vinorelbine tartrate 64 rituximab refractory 64 docetaxel Taxotere R 64 ULORIC 64 demethylating agent 64 CoFactor 64 Topotecan 64 Zyclara 64 Fluorouracil 64 ancrod 64 Fludara ® 64 antiangiogenic therapy 64 oral diclofenac 64 zalutumumab 64 CYT# potent vascular disrupting 64 Vidaza R 64 crizotinib PF # 64 peginterferon alpha 2a 64 Bortezomib 64 ganetespib 64 trastuzumab Herceptin 64 TREANDA 64 Taxotere docetaxel 64 YERVOY 64 HBeAg + 64 lanthanum carbonate 64 cilengitide 64 dose cohort 64 radiotherapy RT 64 EndoTAGTM 1 64 fluvastatin 64 refractory multiple myeloma 64 metaglidasen 64 viral kinetics 64 taxane refractory 64 favorable pharmacokinetic profile 64 beta 1a 64 gp# vaccine 64 darunavir ritonavir 64 remission CR 64 Sanofi Aventis Taxotere 64 chemotherapy cisplatin 64 huN# DM1 64 nucleoside analog 64 FLT3 ITD 64 refractory metastatic colorectal cancer 64 KRAS wild 64 neoadjuvant chemotherapy 64 lopinavir r arm 64 hematologic toxicity 64 MetMAb 64 infusional 64 abiraterone acetate 64 IMA# 64 colorectal liver metastases 64 EFAPROXYN 64 davunetide intranasal AL 64 milatuzumab 64 androgen independent 64 relapsed ALL 64 Cyclophosphamide 64 AEGR 64 trabectedin 64 refractory ovarian cancer 64 eribulin 64 methotrexate monotherapy 64 Eli Lilly Gemzar 64 infusional 5-FU/LV 64 stage IIIb 64 previously untreated follicular 64 #mg/m# [001] 64 HuMax EGFr 64 Pegylated Liposomal Doxorubicin 64 Pegasys peginterferon alfa 2a 64 invasive candidiasis 64 fosbretabulin 64 epirubicin cyclophosphamide 64 tumor xenograft models 64 imatinib therapy 64 locoregional 64 refractory NSCLC 64 VAPRISOL 64 GW# [003] 64 autologous SCT 64 busulfan 64 FOLFOX chemotherapy 64 AVASTIN 64 Camptosar ® irinotecan 64 Mitoxantrone 64 mutated K ras 64 radiochemotherapy 64 Aflibercept 64 Neupogen ® 64 MDS AML 63 aprepitant 63 telaprevir dosed 63 cytostatic 63 olmesartan 63 IIIa inhibitor 63 PROSTVAC VF 63 degarelix 63 Nexavar sorafenib 63 ibritumomab tiuxetan 63 tolvaptan 63 systemic anaplastic large 63 complete remissions 63 fosamprenavir 63 abacavir lamivudine 63 irinotecan chemotherapy 63 prostate cancer HRPC 63 docetaxel 63 trabedersen 63 efavirenz EFV 63 IFN alpha 63 pemetrexed 63 mitoxantrone 63 Epirubicin 63 randomized multicenter Phase III 63 HGS ETR1 63 pegylated interferon alfa 2a 63 sunitinib Sutent 63 sipuleucel T 63 imatinib resistant 63 chemoradiotherapy 63 evaluable patients 63 T#I [002] 63 BEACOPP 63 Targretin capsules 63 EGFR inhibitors 63 Secondary endpoints 63 dose melphalan 63 active comparator 63 genotypic resistance 63 follicular NHL 63 doxorubicin docetaxel 63 IFN beta 63 atazanavir ritonavir 63 chemotherapeutic drug 63 pT3 63 unresectable tumors 63 isoproterenol 63 prostate carcinoma 63 Interferon Beta 63 chemoembolization 63 HBeAg seroconversion 63 recurrent glioblastoma 63 regorafenib 63 YONDELIS 63 desvenlafaxine succinate 63 ceftazidime 63 KRAS mutations 63 mg qd 63 NovoTTF 63 plus DOXIL 63 relapsed refractory 63 metastatic renal cell 63 endocrine therapies 63 protease inhibitor PI 63 standard chemotherapy regimens 63 depsipeptide 63 pegylated interferon alfa 2b 63 insulin detemir 63 PREZISTA r 63 plasma uric acid 63 squamous histology 63 Triapine R 63 ON #.Na 63 Thal Dex 63 SVR# 63 Seliciclib 63 Zorbtive TM 63 mcg QD 63 amphotericin B 63 amrubicin 63 colorectal metastases 63 subcutaneously administered 63 ACTEMRA TM 63 PEGylated anti 63 corticosteroid dexamethasone 63 receiving VICTRELIS 63 #mg BID [003] 63 neoadjuvant treatment 63 chemotherapeutic regimens 63 refractory metastatic 63 oral ridaforolimus 63 Rituxan rituximab 63 adjunctive placebo 63 NEVO ™ 63 CsA 63 Aplidin 63 dosage regimens 63 tanespimycin 63 Roche Xeloda 63 idraparinux 63 Capesaris 63 urocortin 2 63 bosutinib 63 Relapsed Refractory 63 TNF α 63 ovarian carcinoma 63 CBLC# 63 virological response 63 receptor inhibitor 63 lenalidomide Revlimid R 63 Xeloda ® 63 hydroxymethyl coenzyme 63 -#.# log# 63 interferon alfa 2a 63 IFN alfa 63 TAXUS Express Stent 63 dosing cohort 63 Ophena TM 63 3mg/kg 63 tumors GIST 63 alefacept 63 Gleevec imatinib mesylate 63 abatacept Orencia 63 oral prodrug 63 cytotoxic chemotherapy 63 haematologic 63 Retreatment 63 CDK inhibitor 63 INCB# [003] 63 undetectable HBV DNA 63 Engerix B 63 receiving prophylactic anticoagulation 63 allogeneic transplant 63 rizatriptan 63 letrozole Femara 63 #mg dose [001] 63 locoregional disease 63 platelet inhibitor 63 EndoTAG TM -1 63 AEG# 63 Stage IIIb 63 Cytoxan 63 CTAP# Capsules 63 evaluating Xcytrin 63 taxotere 63 FIRMAGON 63 % CI #.#-#.# [003] 63 chemotherapeutic regimen 63 lung metastases 63 Doxorubicin 63 Pegasys plus Copegus 63 neoadjuvant therapy 63 inhibitor RG# 63 trans retinoic acid 63 hypomethylating agents 63 metastatic malignant melanoma 63 mTOR inhibitor 63 plus prednisone prednisolone 63 μg dose 63 vitro cytotoxicity 63 FOLFIRI alone 63 fluticasone salmeterol 63 DAVANAT 63 epirubicin 63 vincristine doxorubicin 63 radezolid 63 Bosutinib 63 intravenously administered 63 bevacizumab Avastin 63 cytoreductive nephrectomy 63 insulin glulisine 63 liver metastases 63 paclitaxel poliglumex 63 KRAS mutant tumors 63 GRASPA ® 63 HERCEPTIN 63 UPLYSO 63 BENICAR HCT 63 metastatic pancreatic 63 durable remissions 63 amifostine 63 remission induction 63 interferon alfa 2b 63 nonnucleoside reverse transcriptase inhibitors 63 dexamethasone Decadron 63 recurrent NSCLC 63 octreotide LAR 63 Leucovorin 63 PEG SN# 63 Vaprisol 63 virologic response 63 TO AVOID PREGNANCY WHILE 63 Peginterferon alfa 2b 63 evaluable 63 prednisone prednisolone 63 Omacetaxine 63 severe neutropenia 63 pharmacologically active isomer 63 #mg BID [001] 63 fallopian tube carcinoma 63 relapsed acute myelogenous 63 HER2 receptor 63 tenofovir emtricitabine 63 imatinib mesylate Gleevec 63 xenograft models 63 acute GvHD 62 pyrazinamide 62 imipenem 62 HBeAg positive 62 dacarbazine chemotherapy 62 temozolomide Temodar 62 gefitinib 62 liposomal amphotericin B 62 tamoxifen Nolvadex ® 62 Gefitinib 62 Imprime PGG 62 BEXXAR Therapeutic Regimen 62 Annamycin 62 hepatic metastases 62 Meets Primary Endpoint 62 LHRH receptor positive 62 salmeterol fluticasone 62 Pegylated interferon 62 trastuzumab 62 doxorubicin 62 leukemia ALL 62 myelodysplastic myeloproliferative diseases 62 Azedra 62 neratinib 62 Gleevec Glivec 62 TTF Therapy 62 calcineurin inhibitor 62 biologic DMARD 62 Cisplatin 62 low dose ritonavir 62 mTOR inhibitors 62 chemotherapy FOLFOX 62 virologic failure 62 canakinumab 62 Dacogen decitabine 62 PASI scores 62 tobramycin 62 Kinoid 62 alvespimycin 62 pharmacodynamic PD 62 SCCHN 62 microbiological eradication 62 Telcyta 62 satraplatin Phase 62 CYPHER Stent 62 imiquimod cream 62 5 HT2C receptor 62 Onconase 62 ® lenalidomide 62 interferon gamma 1b 62 candesartan cilexetil 62 resected pancreatic cancer 62 targeted antifolate 62 enfuvirtide 62 HSCT 62 glufosfamide 62 thalidomide dexamethasone 62 Mitomycin C 62 lymphocytosis 62 vandetanib 62 interferon IFN 62 Median progression 62 Tarceva erlotinib 62 rosuvastatin #mg 62 Parathyroid Hormone 62 nonmetastatic 62 FOR FURTHER INFORMATION ABOUT 62 cidofovir 62 meropenem 62 NXL# 62 endoscopic remission 62 Neulasta ® 62 median PFS 62 R# #mg BID 62 talabostat 62 enzastaurin 62 stavudine d4T 62 peginterferon 62 adenoma recurrence 62 locoregional control 62 PREZISTA rtv 62 pharmacokinetic PK study 62 levosimendan 62 G#DT 62 Dacogen injection 62 ACZ# 62 cytogenetic response 62 HuLuc# 62 IMiDs ® compound 62 anastrazole 62 Ixempra 62 rFSH 62 pegylated liposomal doxorubicin PLD 62 Gastrointestinal Stromal Tumors 62 Avastin Tarceva 62 Adefovir 62 completely resected 62 underwent surgical resection 62 advanced hepatocellular carcinoma 62 DOXIL ® 62 CD# antibody [001] 62 trans retinoic acid ATRA 62 relapsed refractory AML 62 Everolimus 62 tyrosine kinase inhibitor 62 anthracycline containing 62 cyclophosphamide doxorubicin 62 IOP lowering 62 Hazard Ratio 62 sunitinib Sutent ® 62 FEMALES SHOULD BE ADVISED 62 adefovir dipivoxil 62 DAS# CRP 62 KRAS status 62 docetaxel cisplatin 62 nucleoside analogs 62 HCV replicon 62 EZN 62 VIDAZA 62 Prolongs Survival 62 selective modulator 62 serum calcium levels 62 preoperative chemotherapy 62 evaluating picoplatin 62 tumor regression 62 PEGylated Fab fragment 62 Rituximab 62 AMN# [001] 62 small lymphocytic lymphoma 62 budesonide foam 62 Revlimid lenalidomide 62 Patients Treated With 62 Vinorelbine 62 cetuximab 62 AXIRON ™ 62 BARACLUDE ® 62 q8h 62 vidofludimus 62 epoprostenol 62 huC# DM4 62 cisplatin carboplatin 62 BENICAR 62 stage IIIB 62 Ozarelix 62 TELCYTA 62 Herceptin trastuzumab 62 alteplase 62 Tesmilifene 62 hepatoma 62 rhIL 7 62 mg/m2 IV 62 antibody MAb 62 XYOTAX TM 62 relapsed AML 62 TNF Tumor Necrosis Factor 62 FluCAM arm 62 multiple myeloma MM 62 PSADT 62 peak plasma concentrations 62 CIMZIA TM certolizumab pegol 62 NNRTI resistance 62 voriconazole 62 colorectal carcinoma 62 mg ustekinumab 62 CA4P 62 #mg/m# [002] 62 Caelyx 62 novel VDA molecule 62 mcg BID 62 cisplatin 62 atypical hemolytic uremic syndrome 62 nodal metastasis 62 chemotherapy gemcitabine 62 Interferon alfa 62 Exemestane 62 surgical debulking 62 effector function 62 TELINTRA 62 GLIADEL R Wafer 62 thymalfasin 62 β blockers 62 underwent resection 62 pT2 62 denileukin diftitox 62 leuprorelin 62 chronic lymphocytic leukemia CLL 62 cetuximab Erbitux 62 rimonabant #mg 62 custirsen 62 refractory chronic myeloid 62 HoFH 62 TRAIL R2 62 timolol 62 lipid lowering agents 62 Sym# 62 eribulin mesylate 62 Aloxi injection 62 Multiple Myeloma MM 62 lintuzumab 62 panitumumab 62 xanthine oxidase inhibitor 62 BRAF inhibitor 62 nodular partial response 62 S/GSK# 62 EURIDIS 62 CCX# 62 alpha folate receptor 62 nilotinib Tasigna 62 Neoadjuvant 62 GMX# 62 QD dosing 62 Darusentan 62 FOLFOX4 alone 62 pain palliation 62 verteporfin 62 thrombocytopenic 62 alicaforsen enema 62 sunitinib 62 chemoresistant 62 recurrent metastatic 62 Ceplene/IL-2 62 HRPC 62 Albuferon TM 62 splenectomized 62 Omnitarg 62 icatibant 62 farletuzumab 62 NOD SCID mice 62 Imatinib 62 temsirolimus Torisel ® 62 molecularly targeted 62 octreotide 62 p# biomarker 62 Antitumor Activity 62 deferoxamine 62 overlapping toxicities 62 pharmacodynamics PD 62 INC# 62 anti EGFR antibody 62 response CCyR 62 mCi kg 62 CLORETAZINE TM VNP#M 62 IL# PE#QQR 62 imexon 62 APTIVUS 62 HER2 overexpression 62 otamixaban 62 pyridostigmine 62 Quinamed 62 Kepivance 62 HyperAcute 62 ACAPODENE 62 herpetic keratitis 61 mertansine 61 basal cell carcinoma BCC 61 GnRH agonist 61 GRN# 61 pancreatic neuroendocrine tumors 61 Tyrima 61 nondiabetic patients 61 oxycodone CR 61 Zarnestra 61 HBeAg negative 61 uric acid lowering 61 L asparaginase 61 LHRH agonist 61 Cutaneous T 61 HuMax CD# 61 Orally administered 61 CanAg 61 mg m² 61 Archexin 61 plus methotrexate 61 TRAIL R1 61 LymphoStat B belimumab 61 Hycamtin 61 Prograf ® 61 sorafenib tablets 61 pan HDAC inhibitor 61 cytotoxic therapy 61 Solid Tumors criteria 61 Fluconazole 61 Cytarabine 61 therapeutic regimens 61 PEG interferon 61 PKC# 61 ascending dose 61 pancreatic carcinoma 61 GPIIb IIIa 61 vWF 61 radiolabeled monoclonal antibody 61 glioblastoma tumors 61 liver histology 61 Granulocyte Colony Stimulating Factor 61 gemcitabine 61 GOUT 61 pegylated interferons 61 aspirin clopidogrel 61 chemotherapy docetaxel 61 Onrigin 61 Zolinza 61 relapsing multiple sclerosis 61 monoclonal antibody conjugated 61 BEXXAR 61 cisplatin resistant 61 weekly subcutaneous injections